Comparison of a Contemporary Sirolimus-eluting Stent (ihtDES-tiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

NCT07190690

Status	RECRUITING
Phase	Not Applicable
Sponsor	Fundación EPIC
Enrollment	2,100 participants

Key Eligibility Criteria

Inclusion (4)

- Patients aged e18 years, and
- Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and
- Patients with de novo lesions in vessels with a reference diameter of e2.25 mm and d4.5 mm in whom implantation of one or more DES is clinically indicated, and
- Patients who have been informed of the characteristics of the study and have provided written informed consent.

Exclusion (8)

- Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis).
- Patients unable to provide informed consent.
- Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.
- Patients with active bleeding at the time of PCI requiring medical attention.
- Patients with planned surgery within the next 3 months.

... and 3 more (see full listing online)

Locations (12 total)

Hospital Universitario San Juan Alicante, Alicante, Spain
Hospital Universitari Germans Trias I Pujol, Badalona, Spain
Hospital Universitari Vall d'Hebron, Barcelona, Spain
... and 9 more locations